A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Selumetinib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 31 Jan 2019 Planned End Date changed from 1 May 2017 to 1 Dec 2020.
- 31 Jan 2019 Planned primary completion date changed from 1 Nov 2016 to 1 Jan 2020.
- 31 Jan 2019 Status changed from recruiting to active no longer recruiting.